Addendum
Ingenol mebutate (actinic keratosis) - Addendum to Commission A18-55
Report documents
-
Addendum
Ingenol mebutate (actinic keratosis) - Addendum to Commission A18-55
Dossier assessment
Indication:
Patients with non-hyperkeratotic, non-hypertrophic actinic keratosis
Result of dossier assessment:
Conclusion of dossier assessment A18-55 unchanged
Additional information
Federal Joint Committee (G-BA)
20 August 2020: The G-BA’s decision of 21 February 2019 was cancelled.
G-BA documents on this decision
Project details
- Project no.
- A19-02
- Commission
- Commission awarded on 07.01.2019 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Ingenol mebutate (actinic keratosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed